Finance

Lists
Why is AQST down 2.72%?
Dive Deeper
AQST:NASDAQ
Aquestive Therapeutics Inc
US$4.12
-2.72%
(-0.12) 1D
ኦክቶ 29, 12:31:29 ከሰዓት ጂ ኤም ቲ-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AQST...
Open
US$4.17
High
US$4.29
Low
US$4.11
Mkt. cap
516.48 ሚ
Avg. vol.
2.18 ሚ
Volume
758.78 ሺ
52-wk high
US$6.92
52-wk low
US$2.93
EPS
-US$0.65
Beta
1.49
Shares outstanding
125.51 ሚ
No. of employees
147
Open
US$4.17
High
US$4.29
Low
US$4.11
Mkt. cap
516.48 ሚ
Avg. vol.
2.18 ሚ
Volume
758.78 ሺ
52-wk high
US$6.92
52-wk low
US$2.93
EPS
-US$0.65
Beta
1.49
Shares outstanding
125.51 ሚ
No. of employees
147
News stories
From web sources and news partners
About Aquestive Therapeutics Inc
CEO-
Employees147
Founded2004
HeadquartersWarren, ኒው ጄርዚ, ዩናይትድ ስቴትስ
SectorPharmaceutical industry
Websiteaquestive.com
Analyst ratings
Based on 3 analysts giving stock ratings to AQST in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for AQST in the last 3 months.
Highest
Current US$4.12
US$10.00 (+143.01%)
Average
US$8.67 (+110.69%)
Lowest
US$6.00 (+45.81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$10.00
+143%
10/16/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
US$10.00
+143%
09/17/2026
Thomas Flaten
Lake Street
Buy
Maintained
US$6.00
+45.8%
09/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
US$11.00
+167.3%
06/25/2026
Andreas Argyrides
Chardan Capital
Buy
Reiterated
US$8.00
+94.4%
06/25/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
US$9.00
+118.7%
05/15/2026
David Amsellem
Piper Sandler
Buy
Reiterated
US$8.00
+94.4%
05/15/2026
James Molloy
Alliance Global Partners
Buy
Maintained
US$9.00
+118.7%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
12.81 ሚ
13.02 ሚ
14.45 ሚ
13.82 ሚ
Cost of goods sold
4.51 ሚ
5.84 ሚ
3.47 ሚ
4.02 ሚ
Cost of revenue
4.51 ሚ
5.84 ሚ
3.47 ሚ
4.02 ሚ
Research and development expenses
4.53 ሚ
3.20 ሚ
4.20 ሚ
3.96 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.25 ሚ
32.82 ሚ
10.98 ሚ
14.06 ሚ
Operating expense
19.78 ሚ
36.02 ሚ
15.18 ሚ
18.02 ሚ
Total operating expenses
24.29 ሚ
41.85 ሚ
18.65 ሚ
22.04 ሚ
Operating income
-11.48 ሚ
-28.84 ሚ
-4.20 ሚ
-8.22 ሚ
Other non operating income
-
-
-
-
EBT including unusual items
-15.45 ሚ
-31.86 ሚ
-8.06 ሚ
-22.86 ሚ
EBT excluding unusual items
-15.45 ሚ
-31.86 ሚ
-8.06 ሚ
-11.18 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.45 ሚ
-31.86 ሚ
-8.06 ሚ
-22.86 ሚ
Net profit margin
-120.61%
-244.79%
-55.77%
-165.45%
Earnings per share
-0.11
-0.14
-0.05
-0.07
Interest and investment income
306.00 ሺ
1.25 ሚ
83.00 ሺ
882.00 ሺ
Interest expense
-4.27 ሚ
-4.27 ሚ
-3.94 ሚ
-3.84 ሚ
Net interest expenses
-3.97 ሚ
-3.02 ሚ
-3.85 ሚ
-2.96 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.34 ሚ
-28.68 ሚ
-4.09 ሚ
-8.09 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google መተግበሪያዎች